Company profile
Scholar Rock Holding Corporation
NASDAQ: SRRK · Healthcare · Biotechnology
#1166 of 1,422 Healthcare companies by revenuebottom-decile growth
EA Score
40DFH 43DQ 40GM 15SS 70
v0.1 · 65/100 weight · provisional
↑ market scale, Altman-Z · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$377.9M
Employees
289
as of 2026-08-06
Market cap
$5.7B
as of 2026-08-06
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$377.9M-$377.9M2025
Operating income-$384.6M-$384.6M2025
Total assets$404.3M$404.3M2025
Liabilities$158.8M$158.8M2025
Equity$245.5M$245.5M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Scholar Rock Holding Corporation’s revenue?
Scholar Rock Holding Corporation booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Spyre Therapeutics, Inc.64CPraxis Precision Medicines, Inc.61COruka Therapeutics, Inc.66BDenali Therapeutics Inc.52DViking Therapeutics, Inc.69BAmylyx Pharmaceuticals, Inc.51DNeighbors
Middlesex →Key facts
CEODavid L. Hallal
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: SRRK
Employees289
IPO date2018-05-25
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.